콘텐츠로 건너뛰기
Merck
  • The aberrant expression of cytosolic carbonic anhydrase and its clinical significance in human non-small cell lung cancer.

The aberrant expression of cytosolic carbonic anhydrase and its clinical significance in human non-small cell lung cancer.

Cancer letters (2002-10-31)
Whei Ling Chiang, Shu Chen Chu, Shyh Sheng Yang, Mu Chun Li, Jyh Chang Lai, Shun Fa Yang, Hui Ling Chiou, Yih Shou Hsieh
초록

This study was designed to elucidate the possible relationship between the expression of cytosolic carbonic anhydrase (CA) and non-small cell lung cancer (NSCLC). The activity and protein expression patterns of carbonic anhydrase I (CAI) and II (CAII) of 70 NSCLC patients were analyzed by CA activity analysis, immunoblotting and immunohistochemical staining. The results showed that the CA activity and protein expression were significantly decreased in both squamous cell carcinoma (SCC) and adenocarcinoma (AD) (P<0.001 and P<0.001). From our study, it was suggested that the reduction of CAI and CAII in both SCC and AD patients may promote tumor cell motility and contribute to tumor growth and metastasis.

MATERIALS
제품 번호
브랜드
제품 설명

Sigma-Aldrich
Carbonic Anhydrase I from human erythrocytes
Sigma-Aldrich
Carbonic Anhydrase II human, recombinant, expressed in E. coli, buffered aqueous solution
Sigma-Aldrich
Carbonic Anhydrase Isozyme II human, ≥80%, powder, ≥3,000 W-A units/mg protein